PT - JOURNAL ARTICLE AU - Gu, Tian AU - Chu, Qiao AU - Yu, Zhangsheng AU - Fa, Botao AU - Li, Anqi AU - Xu, Lei AU - He, Yaping AU - Wu, Ruijun TI - History of Coronary Heart Disease Increases the Mortality Rate of Coronavirus Disease 2019 (COVID-19) Patients: A Nested Case-Control Study Based on Publicly Reported Confirmed Cases in Mainland China AID - 10.1101/2020.03.23.20041848 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.23.20041848 4099 - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041848.short 4100 - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041848.full AB - Background China has experienced an outbreak of a novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since December 2019, and it was announced a worldwide pandemic in March 2020. There is limited evidence on the mortality risk effect of pre-existing comorbidity for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for early treatment.Objective To evaluate the risk of the common preexisting comorbidities, including hypertension, coronary heart diseases (CHD), respiratory diseases and diabetes on COVID-19 mortality, and provide clinical suggestions accordingly.Method This study used a nested case-control design to assess the impact of pre-existing comorbidities on the hazard of COVID-19 in mainland China. A total of 321 publicly reported confirmed cases (146 cases and 175 controls) with trackable time-to-death information and history of comorbidities were collected between December 18th, 2019 and March 8th, 2020. Each case was matched with three controls on gender and age ±3 years old. Inverse probability weighted Cox proportional hazard model was used to assess the death risk of comorbidities of interest.Results History of comorbidity significantly increases the death risk of COVID-19: one additional pre-existing comorbidity will lead to an estimated 29% higher risk of death (p=0.01). Patients with CHD had a 92% higher risk of mortality, compared to patients without CHD (p=0.009), along with an estimated 13 days (95% CI: 11-23 days) of median survival time.Conclusion This study provides substantial evidence, related pathophysiological mechanisms and clinical suggestion for higher mortality risk in COVID-19 patients with pre-existing CHD. Extra care and early medical intervention maybe needed for patients with pre-existing CHD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the National Natural Science Foundation of China (No. 71874111), Shanghai Municipal Health Bureau Foundation (No. 201740116) and Shanghai Jiao Tong University Scientific and Technological Innovation Funds (YG2020YQ01, YG2020YQ06).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code in preparation.